Member Info for NathanR999

Https://www.linkedin.com/posts/colin-barnden-1081376_r1t-r1s-dms-activity-7249746936482729987-PX7d?utm_source=share&utm_medium=member_android

Depends on monitoring service uptake. Install for compliance around regulatory need would be a sale at x margin and then years of arr if guardian monitoring I guess at usual rate.

Will be interesting to see market reaction to this. It is a credit line and they might not need all or any of it (based on the terms and non bank provision then it looks priced to inferred they will need a good dollop of the credit facility). Clearly they couldn't do a raise without a massive discount, last one was a small discount I recall. The market may mark this down to what the price would have been based on a dilution on a big discount. Our next quarters results will be telling - I am expecting growth but reduced due to car sales being hampered by economic climate. IF we show continuing growth as per previous then I think the penny will finally drop that smarteyes design wins are smoke and mirrors. They are clearly selling too cheap and their strategy is unravelling. Some design wins for SEE would be very timely at this point. No sign of this month's ncap scores for new models yet - not sure that really means anything other than euro ncaps website.manager is on holiday.

I think the market cap of Cipia and Tobii have fallen so far they are likely to be needing to be take out before they fail.

They don't have the scale to get enough cashflow to support the constant r and d etc.

If we could do an all share aquisition for both I wouldn't be against personally but Tobii might add some new verticals. A raise to do it in cash would be brutal. Tobii is Swedish too I believe so you could see how a local aquisition maybe easier to digest for smarteye as they maybe have better opportunity to.co locate and remove back office. Cipia has some jurisdiction risk also being based in Israel. If we were at 12/15p and cashflow positive it would be a no trainer for me. But we are not and it would be a riskier move but companies are.listed to raise money and raising money means share issuance. What would be better smarteye acquiring and us doing our thing or see acquiring and taking out 2 competitors th

Qed. Next to no revenues, delays after delays, losses proportionally higher vs market cap than See. But yeah let's pick a fight with see.... and I say this as a holder of both.

He has had quite a few different roles before See. Maybe just gets itchy feet average seems to be 3-4 years per role. We will also have taken on some of the ex Valeo division and maybe that office will do.some of the work and therefore amicable parting of ways or saw writing on wall on managing headcount spend. Who knows. Not a director so unlikely needs a market disclosure.

The general malaise must be contagious, no new cars yet on the euro ncap website even though they said update today. Last one update was live by lunchtime.

Likely to be fund redemption everywhere with it all going to sh@#. Expect some sales by funds everywhere not just LO here. Small caps are gonna bear the brunt.

Wonder when CFP would turn up. Ever insightful as always. Seems to have stopped mentioning QED now mind.......

More new ncap scores tomorrow I believe. God this grind lower is hard work.

What was interesting and I didn't screen shot to back this is that Jesper inferred one of the recent OEMs was VW and inferred issues with mirror dms. This has been removed - clearly happy to stir the pot and almost certainly got threatened by a concerned party VW,magna or see to remove. All will out in time no doubt. Jesper is a clearly talking redeye book and has habit along with Viktor of lobbing unsubstantiated inference into the mix. A nice few announcements on any front would certainly settle the horses.

Redye analyst inferred it was ex30 not ex90 that had cheap chinese system. Much as jesper is a kn@@ i think we have to be correct here.

Unhelpful headwinds yet again mind. We will get quarterly growth but it maybe lower than we expect. Ie we shouldn't be surprised based on macro signs in car industry.

Https://www.redeye.se/research/1041322/smart-eye-preview-q324-expecting-a-soft-quarter-after-industry-weakness?utm_source=note&utm_medium=email¬ificationId=bb2ace43-18a1-420d-bd71-b5cedb121cd5

Redeye prepping the ground for a poor quarter. Prob wise to at least be.mindful of read across for our next quarter. Tough times in car industry.

Warming up for the placing - market hasn't reacted positively like previous announcement. Hopefully we have some awards still to be announced via magna and valeo both offer turnkey options and have really driven uptake at scale of adas and mobileye specifically in the past. A replication of that for us would be most welcome. News before kpi would be most welcome.

Https://www.smarteye.se/investors/press-releases/press-detail/?slug=smart-eye-announces-new-driver-monitoring-system-design-win-with-leading-north-american-car-manufacturer

Sharp drop in smarteye today. Some speculation on Swedish language twitter that speculation on placing or smarteye may try to acquire tobii. Maybe just trader talk but something may have leaked and cash has been of concern so my bet is placing at a discount. How big might give indication on how far they are away from profitable run rate.

I am sure they will sell as many dms solutions to oems as they have FSD LICENCES to other oems......

Quick scoot through the newly added cars. Subaru and xpeng only ones with camera dms. Reast are steering wheel or other indirect method. The xpeng score not good. Suburu 1.4/2 for the driver monitoring.

The year is 2035. Hvivo have announced over 200m revenues, excellent free cash flow, 50m cash (positioned for several bolt on patient recruitment businesses in 2035) dividend is now split into 2 and has been progressively increased since 2029 and now total 2.1p. FDA and EMA now mandate a challenge study for all new respiratory vaccines as part of P1 & 2 data package.

A new floor in CW is now open and several recruitment sites for a wide range of clinical trials are situated around the world as part of the CRO division developed by bolt on acquisitions, Several new Enteric pathogen models have been successfully run last year. Hlab now takes up two floor at CW. A low ball takeover was rebuffed in 2030 at 66p - share price is £1.25

STT is still raising more red flags than the chinese army and going on about CF selling shares. Totally PLC collapsed into administration in late 2025

FLUCAMP monetising looks interesting. Could grow to be decent add on and cover hvivo costs for own trials. Happy with that.

Expanded lab services - happy with that.

Site services for outpatient p3 field studies - happy with that.

Decent explanation on cash/revenue and order book and opportunities.

New models to build out offer - new agents take time to be signed vs current.

Some great comments on new facility being built to help deliver some planned new studies. As an infectious disease scientist the new transmission study capability might be novel in field as a commercial company.

Confirmation that proposals and market still strong. Timing and contract signing difficult to predict.

Uplift from 62 m to 100m. 10m attrib to m &a. HCT growth of 15m lab service 6m uplift. Acquisition is watch and wait for right business rather than a rush to do now.

Hold for 5 yrs and I reckon we will be very happy.

Https://www.linkedin.com/posts/cipia_there-was-a-bit-of-intrigue-a-couple-of-days-activity-7238567769808551937-CYvp?utm_source=share&utm_medium=member_android

https://www.linkedin.com/posts/flespi_there-was-a-bit-of-intrigue-a-couple-of-days-activity-7237804273797877761-bZMA?utm_source=share&utm_medium=member_android